Christenson SA, Smith BM, Bafadhel M, Putcha N (2022) Chronic obstructive pulmonary disease. Lancet 399(10342):2227–2242. https://doi.org/10.1016/S0140-6736(22)00470-6

Article  PubMed  Google Scholar 

Moll M, Silverman EK (2024) Precision approaches to chronic obstructive pulmonary disease management. Annu Rev Med 75:247–262. https://doi.org/10.1146/annurev-med-060622-101239

Article  CAS  PubMed  Google Scholar 

Christenson SA (2023) COPD phenotyping. Respir Care 68(7):871–880. https://doi.org/10.4187/respcare.11035

Article  PubMed  PubMed Central  Google Scholar 

Boers E, Barrett M, Su JG, Benjafield AV, Sinha S, Kaye L, Zar HJ, Vuong V, Tellez D, Gondalia R, Rice MB, Nunez CM, Wedzicha JA, Malhotra A (2023) Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open 6(12):e2346598. https://doi.org/10.1001/jamanetworkopen.2023.46598

Article  PubMed  PubMed Central  Google Scholar 

Tamondong-Lachica DR, Skolnik N, Hurst JR, Marchetti N, Rabe APJ, Montes de Oca M, Celli BR (2023) GOLD 2023 update: implications for clinical practice. Int J Chron Obstruct Pulmon Dis 18:745–754. https://doi.org/10.2147/COPD.S404690

Article  PubMed  PubMed Central  Google Scholar 

Kahnert K, Jörres RA, Behr J, Welte T (2023) The diagnosis and treatment of COPD and its comorbidities. Dtsch Arztebl Int 120(25):434–444. https://doi.org/10.3238/arztebl.m2023.027

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Xu H, Qiao D, DeMeo DL, Silverman EK, O’Connor GT, Hobbs BD, Dupuis J, Cho MH, Moll M (2022) A polygenic risk score and age of diagnosis of COPD. Eur Respir J 60(3):2101954. https://doi.org/10.1183/13993003.01954-2021

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Fei J, Xu J, Cheng ZY, Ma YC, Wu JH, Yang J, Zhao H, Fu L (2024) Associations of the Serum KL-6 with severity and prognosis in patients with acute exacerbation of chronic obstructive pulmonary disease. Lung 202(3):245–255. https://doi.org/10.1007/s00408-024-00702-5

Article  CAS  PubMed  Google Scholar 

Cao P, Zhang C, Hua DX, Li MD, Lv BB, Fu L, Zhao H (2022) Serum 8-hydroxy-2’-deoxyguanosine predicts severity and prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease. Lung 200(1):31–39. https://doi.org/10.1007/s00408-021-00507-w

Article  CAS  PubMed  Google Scholar 

Henry BM, Cheruiyot I, Benoit SW, Sanchis-Gomar F, Lippi G, Benoit J (2022) Cytokeratin 18 cell death assays as biomarkers for quantification of apoptosis and necrosis in COVID-19: a prospective, observational study. J Clin Pathol 75(6):410–415. https://doi.org/10.1136/jclinpath-2020-207242

Article  PubMed  Google Scholar 

Kwak N, Lee KH, Woo J, Kim J, Park J, Lee CH, Yoo CG (2024) Del-1 Plays a protective role against COPD development by inhibiting inflammation and apoptosis. Int J Mol Sci 25(4):1955. https://doi.org/10.3390/ijms25041955

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin L, Song Q, Cheng W, Liu C, Zhou A, Zhou Z, Chen P (2023) MiR-216a reduces apoptosis of pulmonary microvascular endothelial cells in COPD by targeting DNMT1. Tob Induc Dis 21:130. https://doi.org/10.18332/tid/171357

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eguchi A, Iwasa M, Tamai Y, Yamada M, Okuno K, Shigefuku R, Yoshikawa K, Tempaku M, Sakaguchi K, Tanaka H, Sugimoto K, Kobayashi Y, Yamaguchi T, Nakagawa H (2022) The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage. Front Oncol 12:993705. https://doi.org/10.3389/fonc.2022.993705

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaya S, Boydak M, Aydin M, Aras İ (2024) Association between serum cytokeratin 18 and N-terminal procollagen III propeptide in patients with biopsy-proven nonalcoholic fatty liver disease. Biotech Histochem 99(6):313–319. https://doi.org/10.1080/10520295.2024.2385011

Article  CAS  PubMed  Google Scholar 

Dai L, Yan Y, Chen Q (2024) Clinical significance of serum Ck18-M65 and M30 levels in patients with chronic hepatitis B combined with nonalcoholic steatohepatitis and liver fibrosis. Medicine (Baltimore) 103(23):e38342. https://doi.org/10.1097/MD.0000000000038342

Article  CAS  PubMed  Google Scholar 

Menz A, Weitbrecht T, Gorbokon N, Büscheck F, Luebke AM, Kluth M, Hube-Magg C, Hinsch A, Höflmayer D, Weidemann S, Fraune C, Möller K, Bernreuther C, Lebok P, Clauditz T, Sauter G, Uhlig R, Wilczak W, Steurer S, Minner S, Burandt E, Krech R, Dum D, Krech T, Marx A, Simon R (2021) Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. Mol Med 27(1):16. https://doi.org/10.1186/s10020-021-00274-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Petris L, Brandén E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, Lewensohn R, Linder S, Lehtiö J (2011) Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer 47(1):131–137. https://doi.org/10.1016/j.ejca.2010.08.006

Article  CAS  PubMed  Google Scholar 

Lee KS, Choi YH, Kim YS, Baik SH, Oh YJ, Sheen SS, Park JH, Hwang SC, Park KJ (2008) Evaluation of bronchoalveolar lavage fluid from ARDS patients with regard to apoptosis. Respir Med 102(3):464–469. https://doi.org/10.1016/j.rmed.2007.10.001

Article  PubMed  Google Scholar 

Kuo YB, Chang CA, Wu YK, Hsieh MJ, Tsai CH, Chen KT, Chen CY, Chan EC (2009) Identification and clinical association of anti-cytokeratin 18 autoantibody in COPD. Immunol Lett 128(2):131–136. https://doi.org/10.1016/j.imlet.2009.12.017

Article  CAS  PubMed  Google Scholar 

Xiong Y, Gao S, Luo G, Cheng G, Huang W, Jiang R, Wang Y, Cui T (2017) Increased circulating autoantibodies levels of IgG, IgA, IgM against cytokeratin 18 and cytokeratin 19 in chronic obstructive pulmonary disease. Arch Med Res 48(1):79–87. https://doi.org/10.1016/j.arcmed.2017.01.007

Article  CAS  PubMed  Google Scholar 

Tang F, Liu HY, He QY, Liu Y, Lv LP, Fei J, Fu L (2024) Cobalt exposure and pulmonary function reduction in chronic obstructive pulmonary disease patients: the mediating role of club cell secretory protein. Respir Res 25(1):324. https://doi.org/10.1186/s12931-024-02950-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma SX, Xie GF, Fang P, Tang MM, Deng YP, Lu YJ, Cao W, Fu L (2023) Low 15d-PGJ2 status is associated with oxidative stress in chronic obstructive pulmonary disease patients. Inflamm Res 72(2):171–180. https://doi.org/10.1007/s00011-022-01637-4

Article  CAS  PubMed  Google Scholar 

Liu Y, Zhu FM, Xu J, Deng YP, Sun J, He QY, Cheng ZY, Tang MM, Yang J, Fu L, Zhao H (2024) Arsenic exposure and pulmonary function decline: Potential mediating role of TRAIL in chronic obstructive pulmonary disease patients. J Trace Elem Med Biol 83:127415. https://doi.org/10.1016/j.jtemb.2024.127415

Article  CAS  PubMed  Google Scholar 

Liu Z, Ren Q, Mu H, Zeng Y, An Z, He H (2024) Preliminary study on the diagnostic value of LEAP-2 and CK18 in biopsy-proven MAFLD. BMC Gastroenterol 24(1):182. https://doi.org/10.1186/s12876-024-03258-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Cui T, Yang L, Mireskandari M, Knoesel T, Zhang Q, Pacyna-Gengelbach M, Petersen I (2011) The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer. Oncology 80(5–6):333–340. https://doi.org/10.1159/000329098

Article  CAS  PubMed  Google Scholar 

Zhang B, Wang J, Liu W, Yin Y, Qian D, Zhang H, Shi B, Li C, Zhu J, Zhang L, Gao L, Wang C (2016) Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer. J Cancer Res Clin Oncol 142(12):2479–2487. https://doi.org/10.1007/s00432-016-2253-x

Article  CAS